Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer

International Journal of Oncology

Volumn 41, Issue 6, 2012, Pages 2109-2118

  Kawamata, Futoshi ^a   Kamachi, Hirofumi ^a   Einama, Takahiro ^a   Homma, Shigenori ^a   Tahara, Munenori ^a   Miyazaki, Masaya ^a   Tanaka, Shinya ^a   Kamiyama, Toshiya ^a   Nishihara, Hiroshi ^a   Taketomi, Akinobu ^a   Todo, Satoru ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Intracellular localization; Luminal membrane expression; Mesothelin

Indexed keywords

MESOTHELIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BILE DUCT CANCER; BILE DUCT CARCINOMA; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CELLULAR DISTRIBUTION; EXTRAHEPATIC BILE DUCT CANCER; FEMALE; HEMIHEPATECTOMY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LOCAL METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREATICODUODENECTOMY; PERITONEUM METASTASIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SURVIVAL TIME; TUMOR PROMOTION;

AGED; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; FEMALE; GENE EXPRESSION; GPI-LINKED PROTEINS; HUMANS; INTRACELLULAR SPACE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROTEIN TRANSPORT;

EID: 84869773333     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1662     Document Type: Article

References (38)

1. Ito K, Ito H, Allen PJ, et al: Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. Ann Surg 251: 675-681, 2010.
2. Ohashi M, Kusumi T, Sato F, et al: Expression of syndecan-1 and E-cadherin is inversely correlated with poor patient's prognosis and recurrent status of extrahepatic bile duct carcinoma. Biomed Res 30: 79-86, 2009.
3. Jarnagin WR, Fong Y, DeMatteo RP, et al: Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234: 507-519, 2001. (Pubitemid 32946713)
4. Akoad M and Jenkins R: Proximal biliary malignancy. Surg Clin North Am 88: 1409-1428, x-xi, 2008.
5. Veillette G and Castillo CF: Distal biliary malignancy. Surg Clin North Am 88: 1429-1447, xi, 2008.
6. Chang K and Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 93: 136-140, 1996. (Pubitemid 26041483)
7. Chang K, Pastan I and Willingham MC: Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50: 373-381, 1992.
8. Argani P, Iacobuzio-Donahue C, Ryu B, et al: Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7: 3862-3868, 2001. (Pubitemid 34044602)
9. Hassan R, Kreitman RJ, Pastan I and Willingham MC: Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 13: 243-247, 2005. (Pubitemid 41209017)
10. Ordonez NG: Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 16: 192-197, 2003.
11. Ordonez NG: Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 27: 1418-1428, 2003.
12. Einama T, Kamachi H, Nishihara H, et al: Co-Expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas 40: 1276-1282, 2011.
13. Hassan R, Bera T and Pastan I: Mesothelin: a new target for immunotherapy. Clin Cancer Res 10: 3937-3942, 2004. (Pubitemid 38812466)
14. Li M, Bharadwaj U, Zhang R, et al: Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther 7: 286-296, 2008. (Pubitemid 351302523)
15. Cheng WF, Huang CY, Chang MC, et al: High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br J Cancer 100: 1144-1153, 2009.
16. Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R and Brackett D: Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 124: 838-845, 2005. (Pubitemid 41740183)
17. Swierczynski SL, Maitra A, Abraham SC, et al: Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol 35: 357-366, 2004. (Pubitemid 38339611)
18. Baba K, Ishigami S, Arigami T, et al: Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol 105: 195-199, 2012.
19. Einama T, Homma S, Kamachi H, et al: Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer 107: 137-142, 2012.
20. Zhao H, Davydova L, Mandich D, Cartun RW and Ligato S: S100A4 protein and mesothelin expression in dysplasia and carcinoma of the extrahepatic bile duct. Am J Clin Pathol 127: 374-379, 2007. (Pubitemid 46806330)
21. Sobin LH and Wittekind CW (eds): TNM Classification of Malignant Tumors. 6th edition. Wiley-Liss, New York, 2002.
22. Inami K, Kajino K, Abe M, et al: Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. Oncol Rep 20: 1375-1380, 2008.
23. Shimizu A, Hirono S, Tani M, et al: Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci 103: 739-746, 2012.
24. Bharadwaj U, Marin-Muller C, Li M, Chen C and Yao Q: Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis 32: 1013-1024, 2011.
25. Bharadwaj U, Marin-Muller C, Li M, Chen C and Yao Q: Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression. Mol Cancer 10: 106, 2011.
26. Chang MC, Chen CA, Hsieh CY, et al: Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway. Biochem J 424: 449-458, 2009.
27. Hassan R, Schweizer C, Lu KF, et al: Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: implications for cancer therapy. Lung Cancer 68: 455-459, 2010.
28. Bharadwaj U, Li M, Chen C and Yao Q: Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3. Mol Cancer Res 6: 1755-1765, 2008.
29. Inami K, Abe M, Takeda K, et al: Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo. Cancer Sci 101: 969-974, 2009.
30. Yen MJ, Hsu CY, Mao TL, et al: Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 12: 827-831, 2006. (Pubitemid 43259864)
31. Hudis CA: Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 357: 39-51, 2007.
32. Huang TW, Wang CH and Hsieh CB: Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver. Onkologie 30: 129-131, 2007. (Pubitemid 46384542)
33. Sprinzl MF, Schimanski CC, Moehler M, Schadmand-Fischer S, Galle PR and Kanzler S: Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report. BMC Cancer 6: 190, 2006.
34. Bralet MP, Bellin MF, Guettier C, Adam R and Paule B: Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma. Clin Oncol (R Coll Radiol) 18: 426, 2006.
35. Kreitman RJ, Hassan R, Fitzgerald DJ and Pastan I: Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 15: 5274-5279, 2009.
36. Hassan R, Cohen SJ, Phillips M, et al: Phase I clinical trial of the Chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin expressing cancers. Clin Cancer Res 16: 6132-6138, 2010.
37. Hassan R, Bullock S, Premkumar A, et al: Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13: 5144-5149, 2007. (Pubitemid 47502082)
38. Hassan R, Ebel W, Routhier EL, et al: Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 7: 20, 2007.